Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost‏

References

• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646–650.
   PubMed Web of Science ®Google Scholar
• Warriner AH, Patkar NM, Curtis JR, et al. Which fractures are most attributable to osteoporosis? J Clin Epidemiol. 2011 Jan;64(1):46–53.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989 Nov;149(11):2445–2448.
   PubMedGoogle Scholar
• Goldshtein I, Chandler J, Shalev V, et al. Osteoporosis in the community: findings from a novel computerized registry in a large health organization in Israel. J Aging Res Clin Pract. 2015;4:1.
   Google Scholar
• Melmed S, Polonsky KS, Larsen PR, et al. Williams textbook of endocrinology. Philadelphia (PA): Elsevier Health Sciences; 2011.
   Google Scholar
• Kanis J, Johnell O, Odén A, et al. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339:b4229.
   PubMed Web of Science ®Google Scholar
• Nguyen N, Frost S, Center J, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19(10):1431–1444.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Odén A, McCloskey E, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239–2256.
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson‐Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis‐related fractures in the United States, 2005–2025. J Bone Min Res. 2007;22(3):465–475.
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Van Staa T, Ariely R, et al. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009 Oct;20(10):1633–1650.
   PubMed Web of Science ®Google Scholar
• Haentjens P, Autier P, Barette M, et al. The economic cost of hip fractures among elderly women. J Bone Jt Surg. 2001;83(4):493–493.
   PubMed Web of Science ®Google Scholar
• Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009 Feb 4;301(5):513–521.
   PubMed Web of Science ®Google Scholar
• Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007 Jan 24;297(4):387–394.
   PubMed Web of Science ®Google Scholar
• Raebel MA, Schmittdiel J, Karter AJ, et al. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(80 3):S11.
   Google Scholar
• Foundation NO. Clinician’s guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation; 2013.
   Google Scholar
• Fleisch H, Graham R, Russell G, et al. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165(3899):1262–1264.
   PubMed Web of Science ®Google Scholar
• Francis MD, Graham R, Russell G, et al. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969;165(3899):1264–1266.
   PubMed Web of Science ®Google Scholar
• Russell RGG. Bisphosphonates: the first 40years. Bone. 2011;49(1):2–19.
   PubMed Web of Science ®Google Scholar
• Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003 Feb;5(1):65–74.
   PubMedGoogle Scholar
• Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New England J Med. 1995;333(22):1437–1444.
   PubMed Web of Science ®Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004;20(4):433–439.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA. 1998 Dec 23–30;280(24):2077–2082.
   PubMed Web of Science ®Google Scholar
• Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011;49(1):42–49.
   PubMed Web of Science ®Google Scholar
• Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Mineral Res. 2012;27(5):963–974.
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B. A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab. 2008 Jul;93(7):2463–2465.
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23–57.
   PubMed Web of Science ®Google Scholar
• Cosman F, De Beur S, LeBoff M, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.
   PubMed Web of Science ®Google Scholar
• Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON‐Pivotal Fracture Trial (PFT). J Bone Min Res. 2012;27(2):243–254.
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–2938.
   PubMed Web of Science ®Google Scholar
• Mellström D, Sörensen O, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75(6):462–468.
   PubMed Web of Science ®Google Scholar
• Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteoporosis — where do we go from here? New England J Med. 2012;366(22):2048–2051.
   PubMed Web of Science ®Google Scholar
• Sorensen O, Crawford G, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32(2):120–126.
   PubMed Web of Science ®Google Scholar
• Yates J. A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):253–262.
   PubMed Web of Science ®Google Scholar
• Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:1.
   Google Scholar
• Guyatt G, Adachi J, Cranney A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23(4):496–507.
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. New England J Med. 2001 Feb 1;344(5):333–340.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Bergman GJ, Huels J, et al. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011;40:275–284.e2.
   Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1;357(18):1799–1809.
   PubMed Web of Science ®Google Scholar
• Cotté F-E, Mercier F, De Pouvourville G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective case—control analysis. Clin Ther. 2008;30(12):2410–2422.
   PubMed Web of Science ®Google Scholar
• Imaz I, Zegarra P, Gonzalez-Enriquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010 Nov;21(11):1943–1951.
   PubMed Web of Science ®Google Scholar
• Erviti J, Alonso A, Gorricho J, et al. Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study. BMJ Open. 2013;3:2.
   Google Scholar
• Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47(6):749–754.
   PubMed Web of Science ®Google Scholar
• Weycker D, Lamerato L, Schooley S, et al. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Osteoporos Int. 2013;24(4):1483–1489.
   PubMed Web of Science ®Google Scholar
• Crandall C, Newberry S, Gellad W, et al. Treatment to Prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 Report. Comparative effectiveness review no. 53. (Prepared by Southern California Evidence-based practice center under contract no. HHSA-290-2007-10062-I.). Rockville (MD): Agency for Healthcare Research and Quality; 2012.
   Google Scholar
• Levis S, Theodore G. Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm. 2012;18(4Suppl B):S1–15; discussion S13.
   Google Scholar
• Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014 Jan;58:126–135.
   PubMed Web of Science ®Google Scholar
• Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493–1501.
   Google Scholar
• Cramer J, Gold D, Silverman S, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031.
   PubMed Web of Science ®Google Scholar
• Kuzmanova S, Solakov P, Geneva-Popova M. Adherence to bisphosphonate therapy in postmenopausal osteoporotic women. Folia Med. 2011;53:25–31.
   Google Scholar
• Cheen M, Kong M, Zhang R, et al. Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int. 2012;23:1053–1060.
   PubMed Web of Science ®Google Scholar
• Moser SS, Yu J, Goldshtein I, et al. Cost and consequences of nonadherence with oral bisphosphonate therapy findings from a real-world data analysis. Ann Pharmacother. 2016;50:262–269.
   Web of Science ®Google Scholar
• Burden A, Paterson J, Solomon D, et al. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int. 2012;23(3):1075–1082.
   PubMed Web of Science ®Google Scholar
• Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23(1):223–231.
   PubMed Web of Science ®Google Scholar
• Lakatos P, Takács I, Marton I, et al. A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in Hungary. Calcif Tissue Int. 2015;98:215–225.
   PubMed Web of Science ®Google Scholar
• Berecki-Gisolf J, Hockey R, Dobson A. Adherence to bisphosphonate treatment by elderly women. Menopause. 2008;15:984–990.
   PubMed Web of Science ®Google Scholar
• Curtis J, Yun H, Matthews R, et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken). 2012;64:1054–1060.
   PubMed Web of Science ®Google Scholar
• Cadarette S, Solomon D, Katz J, et al. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int. 2011;22(3):943–954.
   PubMed Web of Science ®Google Scholar
• Patrick AR, Brookhart MA, Losina E, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010;95(7):3251–3259.
   PubMed Web of Science ®Google Scholar
• Halkin H, Dushenat M, Silverman B, et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother. 2007;41(1):29–34.
   PubMed Web of Science ®Google Scholar
• Shu AD-H, Stedman MR, Polinski JM, et al. Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care. 2009;15(7):417.
   PubMed Web of Science ®Google Scholar
• Brankin E, Walker M, Lynch N, et al. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin. 2006;22:1249–1256.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis*. Curr Med Res Opin. 2005;21(9):1453–1460.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Lynch NO, Gaudin A-F, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006;28(10):1686–1694.
   PubMed Web of Science ®Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clinic Proc. 2005;80:856–861.
   PubMed Web of Science ®Google Scholar
• Weiss TW, Henderson SC, McHorney CA, et al. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills*. Curr Med Res Opin. 2007;23(9):2193–2203.
   PubMed Web of Science ®Google Scholar
• De Lusignan S, Van Vlymen J, Hague N, et al. Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study. Osteoporos Int. 2006;17(12):1808–1814.
   PubMed Web of Science ®Google Scholar
• Kertes J, Dushenat M, Vesterman JL, et al. Factors contributing to compliance with osteoporosis medication. Isr Med Assoc J. 2008;10(3):207–213.
   PubMed Web of Science ®Google Scholar
• Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19(6):811–818.
   PubMed Web of Science ®Google Scholar
• Sheehy O, Kindundu C, Barbeau M, et al. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int. 2009;20(9):1583–1594.
   PubMed Web of Science ®Google Scholar
• Soong Y-K, Tsai K-S, Huang H-Y, et al. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. 2013;24(2):511–521.
   PubMed Web of Science ®Google Scholar
• Van Den Boogaard C, Breekveldt‐Postma N, Borggreve S, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study*. Curr Med Res Opin. 2006;22(9):1757–1764.
   PubMed Web of Science ®Google Scholar
• Kim SC, Kim M-S, Sanfélix-Gimeno G, et al. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med. 2015;128(5):519–526. e511.
   PubMed Web of Science ®Google Scholar
• LeBlanc E, Rosales A, Balasubramanian A, et al. Risk factors for fracture among current, persistent users of bisphosphonates. Osteoporos Int. 2015;26(2):713–725.
   PubMed Web of Science ®Google Scholar
• Ziller V, Kostev K, Kyvernitakis I, et al. Persistence and compliance of medications used in the treatment of osteoporosis–analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther. 2012;50(5):315–322.
   PubMed Web of Science ®Google Scholar
• Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone. 2012;50(4):870–875.
   PubMed Web of Science ®Google Scholar
• Lin TC, Yang CY, Kao Yang YH, et al. Alendronate adherence and its impact on hip‐fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther. 2011;90(1):109–116.
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Harrold LR, et al. Adherence and occurrence of fractures after switching to once‐monthly oral bisphophonates. Pharmacoepidemiol Drug Saf. 2010;19(12):1233–1240.
   PubMed Web of Science ®Google Scholar
• Copher R, Buzinec P, Zarotsky V, et al. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Curr Med Res Opin. 2010;26(4):777–785.
   PubMed Web of Science ®Google Scholar
• Yeaw J. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–740.
   PubMed Web of Science ®Google Scholar
• Penning-van Beest F, Erkens J, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19(4):511–517.
   PubMed Web of Science ®Google Scholar
• Grazio S, Babic-Naglic D, Kehler T, et al. Persistence of weekly alendronate: a real-world study in Croatia. Clin Rheumatol. 2008;27(5):651–653.
   PubMed Web of Science ®Google Scholar
• Halpern R, Becker L, Iqbal S, et al. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17:25–39.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Min Res. 2008;23(9):1435–1441.
   PubMed Web of Science ®Google Scholar
• Huybrechts K, Ishak K, Caro J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922–928.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003–1008.
   PubMed Web of Science ®Google Scholar
• Olsen K, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases. Osteoporos Int. 2013;24:2639–2647.
   PubMed Web of Science ®Google Scholar
• Wang Z, Ward M, Chan L, et al. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. Osteoporos Int. 2014;25(8):2109–2116.
   PubMed Web of Science ®Google Scholar
• Pazianas M, Abrahamsen B, Wang Y, et al. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporos Int. 2012;23(12):2873–2884.
   PubMed Web of Science ®Google Scholar
• Landfeldt E, Ström O, Robbins S, et al. Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012;23(2):433–443.
   PubMed Web of Science ®Google Scholar
• Devold HM, Furu K, Skurtveit S, et al. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21(3):297–304.
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Adachi JD, Rampakakis E, et al. Long‐term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Min Res. 2012;27(1):202–210.
   PubMed Web of Science ®Google Scholar
• Burden AM, Paterson JM, Gruneir A, et al. Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. Pharmacoepidemiol Drug Saf. 2015;24(1):67–74.
   PubMed Web of Science ®Google Scholar
• Reynolds K, Muntner P, Cheetham TC, et al. Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int. 2013;24(9):2509–2517.
   PubMed Web of Science ®Google Scholar
• Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions and discontinuation. J Managed Care Pharm. 1998;4(5):488–492.
   Google Scholar
• Aki S, Eskiyurtl N, Akarirmakz -I-I, et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med J. 2003;44(6):961–967.
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Stock JL, Barrett‐Connor E, et al. Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial. J Bone Min Res. 2008;23(1):112–120.
   PubMed Web of Science ®Google Scholar
• Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215.
   PubMed Web of Science ®Google Scholar
• Gallagher AM, Rietbrock S, Olson M, et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Min Res. 2008;23(10):1569–1575.
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–1022.
   Google Scholar
• Lindsay R, Watts N, Lange J, et al. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. Osteoporos Int. 2013;24(8):2345–2352.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Nakamura T, Hagino H, et al. Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study. J Bone Miner Metab. 2011;29(5):561–570.
   PubMed Web of Science ®Google Scholar
• Meijer WM, Penning-van Beest FJ, Olson M, et al. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures*. Curr Med Res Opin. 2008;24(11):3217–3222.
   PubMed Web of Science ®Google Scholar
• Blouin J, Dragomir A, Moride Y, et al. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol. 2008;66(1):117–127.
   PubMed Web of Science ®Google Scholar
• Höer A, Seidlitz C, Gothe H, et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence. 2009;3:25.
   PubMed Web of Science ®Google Scholar
• Eastell R, Vrijens B, Cahall D, et al. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res. 2011;26:1662–1669.
   PubMed Web of Science ®Google Scholar
• Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143(10):971–978.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, García-Rodríguez LA, Perez-Gutthann S, et al. Hormone replacement therapy and incidence of acute myocardial infarction A population-based nested case-control study. Circulation. 2000;101(22):2572–2578.
   PubMed Web of Science ®Google Scholar
• Cotté F-E, Fautrel B, De Pouvourville GA. Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Mak. 2009;29:125–139.
   PubMed Web of Science ®Google Scholar
• Mahler C, Hermann K, Horne R, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany. J Eval Clin Pract. 2010;16(3):574–579.
   PubMed Web of Science ®Google Scholar
• Silverman SL, Gold DT, Cramer JA. Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies. South Med J. 2007 Dec;100(12):1214–1218.
   PubMed Web of Science ®Google Scholar
• Eisenberg DF, Placzek H, Gu T, et al. Cost and consequences of noncompliance to oral bisphosphonate treatment. J Manag Care Spec Pharm. 2015;21(1):56–65.
   PubMed Web of Science ®Google Scholar
• Vanna JJ, Feaganes J, Wegner S. Reliability of Medicaid claims versus medical record data. Pharmacoeconomics. 2007;25(9):793–800.
   PubMed Web of Science ®Google Scholar
• Modi A, Siris E, Tang J, et al. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Curr Med Res Opin. 2015;31:757–765.
   PubMed Web of Science ®Google Scholar
• Sunyecz J, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int. 2008;19:1421–1429.
   PubMed Web of Science ®Google Scholar
• McCombs J, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271–287.
   PubMed Web of Science ®Google Scholar
• Kilgore ML, Morrisey MA, Becker DJ, et al. Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999–2005. J Bone Min Res. 2009;24(12):2050–2055.
   PubMed Web of Science ®Google Scholar
• Rouach V, Gez S, Yu J, et al. Role of side effects, physician involvement and patient perception in discontinuation or switching of oral bisphosphonates. In: Kanis A, Lindsay Reditor. WCO-IOF-ESCEO. Milan: International Osteoporosis Foundation; 2015. p. P674.
   Google Scholar
• Yu J, Goldshtein I, Shalev V, et al. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women. Int J Clin Pract. 2015 Sep;69(9):1007–1014.
   PubMed Web of Science ®Google Scholar
• Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753–761.
   PubMed Web of Science ®Google Scholar
• Reid I, Gamble G, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid. The. J Clin Endocrinol Metab. 2010;95(9):4380–4387.
   PubMed Web of Science ®Google Scholar
• Wark J, Bensen W, Recknor C, et al. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int. 2012;23(2):503–512.
   PubMed Web of Science ®Google Scholar
• Kling JM, Clarke BL, Sandhu NP. Osteoporosis prevention, screening, and treatment: a review. J Women’s Health. 2014;23(7):563–572.
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone and Miner Res. 2005;20:1315–1322.
   Google Scholar
• Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117–1123.
   PubMed Web of Science ®Google Scholar
• Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92(4):1296–1304.
   PubMed Web of Science ®Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6):914–921.
   PubMed Web of Science ®Google Scholar
• Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Imaj-Ramat Gan-. 2003;5(12):859–862.
   Web of Science ®Google Scholar
• Zafran N, Liss Z, Peled R, et al. Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int. 2005;16(11):1375–1383.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Salas M, Hughes D, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int. 2013;24(12):2907–2918.
   PubMed Web of Science ®Google Scholar
• Bianchi M, Duca P, Vai S, et al. Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int. 2015;26(5):1629–1638.
   PubMed Web of Science ®Google Scholar
• Slomian J, Appelboom G, Ethgen O, et al. Can new information and communication technologies help in the management of osteoporosis? Women’s Health. 2014;10(3):229–232.
   Google Scholar
• Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992 Nov;2(6):285–289.
   PubMed Web of Science ®Google Scholar
• Siggeirsdottir K, Aspelund T, Jonsson B, et al. Epidemiology of fractures in Iceland and secular trends in major osteoporotic fractures 1989–2008. Osteoporos Int. 2014;25(1):211–219.
   PubMed Web of Science ®Google Scholar
• Ballane G, Cauley JA, Luckey MM, et al. Secular trends in hip fractures worldwide: opposing trends East versus West. J Bone Min Res. 2014;29(8):1745–1755.
   PubMed Web of Science ®Google Scholar